Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mycophenolate mofetil in systemic vasculitis.

D P D'Cruz1

  • 1The Rayne Institute, St Thomas' Hospital, London, UK. david.d'cruz@kcl.ac.uk

Lupus
|April 5, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

British Association of Dermatologists guidelines for the management of people with cutaneous lupus erythematosus 2021.

The British journal of dermatology·2021
Same author

Proton pump inhibitor-induced subcutaneous lupus erythematosus in a patient with systemic lupus erythematosus.

Clinical and experimental dermatology·2015
Same author

Increased risk of vascular complications in Takayasu's arteritis patients with positive lupus anticoagulant.

Scandinavian journal of rheumatology·2014
Same author

Morbidity and mortality associated with subglottic laryngotracheal stenosis in granulomatosis with polyangiitis (Wegener's granulomatosis): a single-centre experience in the United Kingdom.

The Journal of laryngology and otology·2014
Same author

Scleroderma and breast implants.

QJM : monthly journal of the Association of Physicians·2014
Same author

Cardiac complications of Behcet's disease.

Clinical rheumatology·2014
Same journal

Association of systemic lupus erythematosus with 90-day readmission following heart failure hospitalization: A national readmission database (NRD) analysis, 2016-2017.

Lupus·2026
Same journal

Association of GPX4 rs713041 and rs4807542 polymorphisms and serum GPX4 levels in Chinese patients with systemic lupus erythematosus.

Lupus·2026
Same journal

Giant cell myocarditis in an 18-year-old patient with new-onset systemic lupus erythematosus: A fatal case of rapidly progressing heart failure.

Lupus·2026
Same journal

An evidence-based specialist nursing protocol for children with hypoprothrombinemia-lupus anticoagulant syndrome (HLAS) and its application research.

Lupus·2026
Same journal

T-bet expression in B cell subsets: Association with T peripheral helper cells and clinical activity in systemic lupus erythematosus.

Lupus·2026
Same journal

Autonomic dysfunction in systemic lupus erythematosus and systemic sclerosis.

Lupus·2026
See all related articles

Systemic vasculitides involve vascular inflammation and are serious autoimmune diseases. This review examines the use of mycophenolate mofetil (MMF) for treating these conditions, offering an alternative to traditional therapies.

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Background:

  • Systemic vasculitides are severe autoimmune diseases causing inflammation in blood vessels.
  • Current treatments include corticosteroids and cyclophosphamide for induction, with azathioprine and methotrexate for maintenance.
  • Mycophenolate mofetil (MMF) is gaining traction in managing autoimmune disorders.

Purpose of the Study:

  • To review the current applications and efficacy of mycophenolate mofetil (MMF) in treating systemic vasculitides.
  • To provide insights into MMF's role as a therapeutic option for these complex autoimmune conditions.

Main Methods:

  • Literature review of studies investigating MMF in systemic vasculitides.
  • Analysis of clinical trial data and case reports on MMF usage.

Related Experiment Videos

  • Synthesis of evidence regarding MMF's efficacy and safety profile.

    • Main Results:

    • MMF demonstrates potential as an effective agent in managing systemic vasculitides.
    • Evidence suggests MMF can be used for both induction and maintenance of remission.
    • MMF offers a viable alternative or adjunct to established treatments, potentially with a favorable side-effect profile.

    Conclusions:

    • Mycophenolate mofetil (MMF) is a promising therapeutic option for systemic vasculitides.
    • Further research is warranted to fully elucidate MMF's long-term efficacy and optimal use in vasculitis management.
    • MMF represents a valuable addition to the treatment armamentarium for autoimmune vascular inflammation.